Northern Trust Corp Sage Therapeutics, Inc. Transaction History

Northern Trust Corp

$586 Billion
Q2 2024

A detailed history of Northern Trust Corp transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 490,525 shares of SAGE stock, worth $3.54 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

490,525

Previous 526,333 6.8%

Holding current value

$3.54 Million

Previous $9.86 Million 45.99%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$10.58 - $17.9 $378,848 - $640,963	-35,808 Reduced 6.8%	490,525 $5.33 Million
Q1 2024 May 14, 2024	SELL	$18.62 - $26.95 $303,934 - $439,904	-16,323 Reduced 3.01%	526,333 $9.86 Million
Q4 2023 Feb 13, 2024	SELL	$17.1 - $22.26 $1.49 Million - $1.94 Million	-87,122 Reduced 13.83%	542,656 $11.8 Million
Q3 2023 Nov 13, 2023	SELL	$16.75 - $48.98 $92,543 - $270,614	-5,525 Reduced 0.87%	629,778 $13 Million
Q2 2023 Aug 11, 2023	BUY	$40.65 - $59.54 $1.62 Million - $2.37 Million	39,871 Added 6.7%	635,303 $29.9 Million
Q1 2023 May 15, 2023	SELL	$37.27 - $46.57 $387,347 - $484,002	-10,393 Reduced 1.72%	595,432 $25 Million
Q4 2022 Feb 13, 2023	SELL	$32.2 - $43.61 $12,590 - $17,051	-391 Reduced 0.06%	605,825 $23.1 Million
Q3 2022 Nov 14, 2022	BUY	$32.28 - $43.27 $72,855 - $97,660	2,257 Added 0.37%	606,216 $23.7 Million
Q2 2022 Aug 12, 2022	BUY	$27.52 - $37.99 $9.4 Million - $13 Million	341,525 Added 130.14%	603,959 $19.5 Million
Q1 2022 May 13, 2022	SELL	$30.71 - $45.71 $241,964 - $360,149	-7,879 Reduced 2.91%	262,434 $8.69 Million
Q4 2021 Feb 08, 2022	BUY	$37.06 - $47.11 $48,437 - $61,572	1,307 Added 0.49%	270,313 $11.5 Million
Q3 2021 Nov 15, 2021	SELL	$40.26 - $57.37 $225,254 - $320,985	-5,595 Reduced 2.04%	269,006 $11.9 Million
Q2 2021 Aug 13, 2021	SELL	$54.88 - $79.29 $246,356 - $355,932	-4,489 Reduced 1.61%	274,601 $15.6 Million
Q1 2021 May 12, 2021	SELL	$70.65 - $96.76 $900,081 - $1.23 Million	-12,740 Reduced 4.37%	279,090 $20.9 Million
Q4 2020 Feb 11, 2021	SELL	$58.41 - $89.06 $444,324 - $677,479	-7,607 Reduced 2.54%	291,830 $25.2 Million
Q3 2020 Nov 16, 2020	SELL	$41.13 - $62.45 $246,163 - $373,763	-5,985 Reduced 1.96%	299,437 $18.3 Million
Q2 2020 Aug 14, 2020	BUY	$25.95 - $43.15 $1.11 Million - $1.84 Million	42,652 Added 16.23%	305,422 $12.7 Million
Q1 2020 May 14, 2020	BUY	$26.15 - $77.24 $304,464 - $899,305	11,643 Added 4.64%	262,770 $7.55 Million
Q4 2019 Feb 14, 2020	SELL	$60.18 - $154.77 $1.98 Million - $5.1 Million	-32,961 Reduced 11.6%	251,127 $18.1 Million
Q3 2019 Nov 13, 2019	BUY	$140.29 - $189.96 $1.33 Million - $1.8 Million	9,468 Added 3.45%	284,088 $39.9 Million
Q2 2019 Aug 13, 2019	BUY	$157.85 - $183.09 $2.39 Million - $2.77 Million	15,119 Added 5.83%	274,620 $50.3 Million
Q1 2019 May 13, 2019	BUY	$89.33 - $163.65 $3.51 Million - $6.44 Million	39,325 Added 17.86%	259,501 $41.3 Million
Q4 2018 Feb 12, 2019	SELL	$81.94 - $139.71 $14,175 - $24,169	-173 Reduced 0.08%	220,176 $21.1 Million
Q3 2018 Nov 14, 2018	SELL	$138.11 - $169.04 $224,704 - $275,028	-1,627 Reduced 0.73%	220,349 $31.1 Million
Q2 2018 Sep 18, 2018	SELL	$140.36 - $175.76 $380,375 - $476,309	-2,710 Reduced 1.21%	221,976 $34.7 Million
Q2 2018 Aug 14, 2018	SELL	$140.36 - $175.76 $37.7 Million - $47.3 Million	-268,909 Reduced 54.48%	224,686 $35.2 Million
Q1 2018 May 09, 2018	BUY	$152.15 - $192.33 $7.52 Million - $9.51 Million	49,437 Added 11.13%	493,595 $79.5 Million
Q4 2017 Feb 14, 2018	BUY	$60.72 - $167.34 $1.94 Million - $5.35 Million	31,984 Added 7.76%	444,158 $73.2 Million
Q3 2017 Nov 13, 2017	BUY	$61.4 - $88.52 $25.3 Million - $36.5 Million	412,174	412,174 $25.7 Million

Others Institutions Holding SAGE

# of Institutions

217

Shares Held

48.2M

Call Options Held

854K

Put Options Held

195K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $428M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Sage Therapeutics, Inc. Transaction History